at 6 months (p<0.014). Median IQQ bowel subset score improved from 31 at baseline to 41 at 6 months (p<0.005). Significant improvement was also found in the median VIGQ score from 11 at baseline to 3 at 6 months (p=0.001). The median CTCAE rectum bowel mean score for men improved from 1.4 at baseline to 0.9 at 6 months and for women from 1.4 at baseline to 1.3 at 6 months. Pooling male and female data, the CTCAE mean score significantly improved comparing baseline with 6 month scores (p=0.001).

Conclusion GI symptom questionnaire scores significantly improved from baseline to 6 months. This suggests that structured gastroenterological evaluation using an algorithmic approach may improve GI symptoms in this patient group, although a controlled study is necessary to confirm this.

Competing interests None declared.

DOES INVESTIGATING CHRONIC GASTROINTESTINAL SYMPTOMS FOLLOWING PELVIC RADIOThERAPY IDENTIFY TREATABLE DIAGNOSES?

PTU-148

doi:10.1136/gutjnl-2012-302514c.148

1C C Henson,* 2J McLaughlin, 3Y Ang, 4C Babbs, 4J Crampton, 5M Kelly, 5S Lal, 5J Lindi, 6G Whalley, 7R Swindell, 8W Makin, 8S E Davidson. 1Christie Hospital, Manchester, UK; 2University of Manchester, Manchester, UK; 3Salford Royal Foundation Trust, Salford, UK; 4University Hospital of South Manchester NHS Trust, Manchester, UK; 5Pennine Acute Hospitals NHS Trust, Manchester, UK; 6Tameside Hospital NHS Foundation Trust, Ashton under Lyne, UK

Introduction 17,000 patients are treated with radical pelvic radiotherapy per year in the UK. Although 50% develop significant chronic gastrointestinal (GI) symptoms, <20% are referred for gastroenterological evaluation. We aimed to determine the causes of GI symptoms in this patient group.

Methods 60 patients with GI symptoms ≥6 months after radical pelvic radiotherapy were identified from oncology clinics. Those requiring urgent investigation via the 2-week wait pathway were excluded. Baseline characteristics including demographic data, cancer treatment details and symptoms were collected. Patients were referred for gastroenterological evaluation using an algorithmic approach, which involves the identification of all GI symptoms and investigation for all potential causes for the individual symptoms. Details of investigations and diagnoses were collected.

Results 20 men and 36 women with primary gynaecological (31), urological (17) or lower GI (8) tumours were included, with a median age of 58.5 years (range 26.9–81.8). As part of their cancer treatment 15 patients also had brachytherapy, 28 had chemotherapy and 25 had surgery. Patients presented with multiple GI symptoms requiring urgent investigation via the 2-week wait pathway were excluded. Baseline characteristics including demographic data, cancer treatment details and symptoms were collected. Patients were referred for gastroenterological evaluation using an algorithmic approach, which involves the identification of all GI symptoms and investigation for all potential causes for the individual symptoms. Details of investigations and diagnoses were collected.

Conclusion Gastroenterological evaluation identifies significant and potentially treatable diagnoses in patients who develop chronic GI symptoms following pelvic radiotherapy. Some findings are incidental and some are unrelated to previous cancer treatment. GI symptoms in these patients have historically been considered “untreatable”. These data suggest that structured gastroenterological assessment has the potential to improve outcome by identifying these diagnoses and facilitating focussed treatment.

Competing interests None declared.

CAMBRIDGE-MIAMI RISK ASSESSMENT FOR INTESTINAL TRANSPLANTATION

PTU-149

doi:10.1136/gutjnl-2012-302514c.149

1C Pither,* 2R Sivaprakasam, 3H Takahashi, 4S Nishida, 5A Butler, 5J Moon, 5M D Dawwas, 5S Gabe, 5N Jamieson, 6J Woodward, 6E Island, 8A Tzakis, 8S J Middleton. 1Gastroenterology, Cambridge University, Cambridge, UK; 2Transplant Surgery, Cambridge University, Cambridge, UK; 3Transplantation Surgery, University of Miami School of Medicine, Miami, USA; 4Intestinal Failure Unit, St Mark’s Academic Centre, London, UK; 5Gastroenterology, Cambridge University, Cambridge, UK; 6Transplantation Surgery, Department of Surgery, University of Miami School of Medicine, Miami, USA; 7Department of Surgery, University of Miami School of Medicine, Miami, USA

Introduction The Cambridge-Miami (CaMi) preoperative risk assessment score has been previously validated in a small cohort and accurately predicted the survival after intestinal transplantation. We undertook a further validation in a larger cohort of patients.

Methods Co-morbidity and lost venous access are used as putative preoperative risk factors, each scored 0–3 for severity. Patients (72 adults (M:F, 33:39) received an isolated intestinal graft (27), or a cluster graft including intestine (45).

Results Mean (SD) survival was 1501 (1444) days. The Kaplan–Meier analysis of survival revealed a significant inverse association between survival and CaMi score [logrank test for trend, p<0.0001]. Patients were grouped into CaMi scores of 0 and 1, 2 and 3, 4 and 5, 6 and above, and HR [95% CIs] for death (compared to group 0+1) was found to increase as the CaMi score increased; 1.945 (0.7622 to 5.816), 5.075 (3.314 to 36.17) and 15.77 (463.3 to 120100) respectively and was significantly greater than group 0+1 at group 4+5 (p<0.0001).

Conclusion The ability to predict survival from the CaMi score might allow better patient selection, and identify patients for earlier transplantation.

Competing interests None declared.